Hemispherx Publishes Full Report of Three Year Joint Research Program at Japanese NIID
15. Juli 2010 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 15, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") announced that it was publicizing the full technical (unedited) report in Japanese, prepared...
Hemispherx Reports Successful Culmination of Three Year Joint Research Program at Japanese NIID
12. Juli 2010 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 12, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director,...
Hemispherx Biopharma Licenses Platform Technologies to GP Pharm
15. Juni 2010 13:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, June 15, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx"), announced that the Company executed an exclusive revenue sharing Sales,...
Hemispherx Biopharma Prepares Application to Initiate Phase II Clinical Trials in China With Ampligen(R)
17. Mai 2010 06:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 17, 2010 (GLOBE NEWSWIRE) -- As part of its expanding international program Hemispherx Biopharma, Inc. (NYSE Amex:HEB), (the "Company"), announced an agreement with Fountain Medical...
Hemispherx Biopharma to Present at the Rodman Healthcare Conference
13. Mai 2010 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 13, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), today announced that the Company will participate in the Rodman & Renshaw 6th Annual...
Hemispherx Biopharma, Inc. 1st Quarter 2010 Financial Results
07. Mai 2010 16:17 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 7, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced its financial results for the three months ended March 31, 2010. The net loss (including non-cash...
New Independent Data Monitoring Committee Established by Hemispherx to Accelerate Global Drug Development
03. Mai 2010 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 3, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE AMEX:HEB) (the "Company") announced today the formation of an Independent Data Monitoring Committee (DMC) which will...
Hemispherx Biopharma and Max Neeman International Team Initiate Influenza Research Programs
01. April 2010 10:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, April 1, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for...
Stanford University Researcher and Hemispherx Biopharma Consultant Present New Integrative Immunotherapy Approach
23. März 2010 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 23, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced today the publication of an editorial entitled "TLR3 agonists as...
Hemispherx Biopharma Announces 2009 Financial Results
15. März 2010 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 15, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced its financial results for the fiscal year ended December 31, 2009. The net loss...